Company Overview / CI HomeAbout C-TRICompany Overview / CI
Company Profile
CI
 
 
 
 
   
Name C-TRI Co., Ltd.
Representative Directors Kim Wan-joo, Lee Hahn-koo
Date of Foundation 1998.04.23
Number of Employees 153
Paid-in Capital 3.0 Billion Won
Main Business Pharmaceutical venture start-up dedicated to development of new peptide drugs
Headquarter 778-1 Ilpaedong, Gyeonggangro, Namyangju-si, Gyeonggi-do, Korea
Phone : +82-31-557-0001
Home Page http://www.c-tri.co.kr
 
 
“Korea’s first Citrelin OD tablets” are getting off to a strong start with robust sales potential
Strong market foothold in Korea following the launch of Citrelin on March 2015 → Advancement into Chinese pharmaceutical market having 2.2 trillion won → Expansion of additional indications for Parkinson’s disease, Alzheimer's disease, and amyotrophic lateral sclerosis
 
The launch of “Cirudin injection” targeting Korea’s ever-increasing aging population is expected to boost C-TRI’s annual turnover
Increase of aging population → Expansion of local market for myocardial infarction and angina pectoris → Increasing prevalence and relapse rate in related diseases → Expected robust sales of Cirudin injection
 
 
 
 
C-TRI with unlimited growth potential based on peptide platform technology
C-TRI’s proprietary peptide platform technology enables the company to expand the scope of the existing business from amino acids to finished peptide drugs, new drugs and cosmetic products.
 
C-TRI pursuing a two-track strategy “sustained growth in pharmaceutical sector + new growth engine”
Cash-cow pharmaceutical business via production of finished products in Namyangju plant + Realization of quantum jump sales via new growth engine business in Chuncheon biodrug plant